Arcadia Biosciences (NASDAQ:RKDA) Posts Earnings Results, Misses Estimates By $1.31 EPS

Arcadia Biosciences (NASDAQ:RKDA) released its quarterly earnings results on Thursday. The basic materials company reported ($2.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($1.31), FiscalAI reports. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.60 million. Arcadia Biosciences had a negative net margin of 48.15% and a positive return on equity of 37.36%.

Arcadia Biosciences Stock Up 0.9%

NASDAQ:RKDA traded up $0.01 during midday trading on Thursday, hitting $1.07. The company had a trading volume of 5,824 shares, compared to its average volume of 30,662. Arcadia Biosciences has a 52-week low of $0.89 and a 52-week high of $6.71. The stock’s fifty day moving average price is $1.42 and its 200-day moving average price is $2.35. The company has a market capitalization of $2.20 million, a PE ratio of -0.62 and a beta of 0.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Arcadia Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Arcadia Biosciences

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision?breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.